SGLT2 Inhibitors First-Line Type 2 Diabetes BMJ UCL NICE | AcademicJobs
Explore UCL's BMJ-published research driving NICE's recommendation of SGLT-2 inhibitors as first-line for type 2 diabetes, potentially saving 20,000 UK lives yearly.
uk-higher-educationresearch-publication-newshealth-informatics

